cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Lianbio
1 own
Current Price
$0
$0.02
(0.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
264.4M
52-Week High
52-Week High
3.3313
52-Week Low
52-Week Low
1.07
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization264.4M
icon52-Week High3.3313
icon52-Week Low1.07
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio--
What does the Lianbio do?
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn s disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Read More
How much money does Lianbio make?
News & Events about Lianbio.
Globe Newswire
1month ago
SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the promotion of Pascal Qian to the position of Chief Commercial ...
Globe Newswire
1month ago
SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Chinas National Medical Products Administration (NMPA) has ...
Globe Newswire
2 months ago
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing, with data expected mid-year 2023 Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis ongoing, with data expected in the fourth quarter of 2023 ...
Globe Newswire
7 months ago
SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following ...
Zolmax
7 months ago
I-Mab (NASDAQ:IMAB Get Rating) and LianBio (NASDAQ:LIAN Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and ...
Frequently Asked Questions
Frequently Asked Questions
What is Lianbio share price today?
plus_minus_icon
Can Indians buy Lianbio shares?
plus_minus_icon
How can I buy Lianbio shares from India?
plus_minus_icon
Can Fractional shares of Lianbio be purchased?
plus_minus_icon
What are the documents required to start investing in Lianbio stocks?
plus_minus_icon
What is today’s traded volume of Lianbio?
plus_minus_icon
What is today’s market capitalisation of Lianbio?
plus_minus_icon
What is the 52-Week High and Low Range of Lianbio?
plus_minus_icon
What percentage is Lianbio down from its 52-Week High?
plus_minus_icon
What percentage is Lianbio up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.02
(0.73%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00